The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of a new somatostatin analogue, pasireotide (Signifor), for the treatment of Cushing’s disease in patients who cannot have surgery or for whom surgery has not been successful.